Samsung Biologics Achieves Top 1% 'Platinum' in Global ESG Evaluation

Highest Grade Medal Awarded

Samsung Biologics announced on the 22nd that it has been awarded the Platinum Medal, the highest rating given only to the top 1% of companies, in the 2023 ESG (Environmental, Social, and Governance) evaluation by EcoVadis, a global sustainability assessment organization.

Incheon Songdo Samsung Biologics Plant 4 Exterior View
[Photo by Samsung Biologics]

Since its establishment in 2007, EcoVadis has evaluated more than 100,000 companies across 175 countries annually in four areas: environment, labor and human rights, ethics, and sustainable procurement, awarding ratings such as Platinum, Gold, Silver, and Bronze. EcoVadis’s ESG evaluation is globally recognized as a reliable supply chain assessment metric, and global pharmaceutical companies such as GlaxoSmithKline (GSK) and AstraZeneca (AZ) are known to use it as an important criterion to assess the sustainability performance of their suppliers.

Samsung Biologics, which received a Gold rating in the 2022 evaluation, has been promoted to the highest rating, 'Platinum,' in this year's assessment. This rating is given only to the top 1% among approximately 100,000 global companies.

Samsung Biologics was highly evaluated for strategically advancing its ESG policies and ESG reports, as well as for expanding participation in global initiatives such as the Sustainability Market Initiative (SMI) led by the British Royal Family and the United Nations Global Compact (UNGC). The company also reported that strengthening information and physical security activities contributed to the improvement in its score.

In the labor and human rights sector, Samsung Biologics was recognized for systematic operational excellence across policy establishment, action, and reporting. The company implemented ▲labor and human rights policies with diversity and equity ▲policies on working environment and employee health ▲awareness training on prohibition of discrimination and harassment ▲and a two-way communication system between labor and management regarding the working environment.

In addition, Samsung Biologics declared '2050 Net Zero' in 2022, joined RE100, and is leading global sustainable management by serving as the chair of the supply chain sector in SMI. In July last year, it jointly issued an open letter on climate change response with six global pharmaceutical companies including GSK, AZ, and Merck, urging suppliers to actively participate in addressing climate change.

John Rim, CEO of Samsung Biologics, said, “As a result of multifaceted efforts in responding to climate change and systematic supply chain management, our ESG competitiveness has been internationally recognized. We will further strengthen sustainable management and fulfill our social responsibilities as a global top-tier Contract Development and Manufacturing Organization (CDMO).”

This content was produced with the assistance of AI translation services.